Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Colistin resistance in carbapenem non-susceptible Acinetobacter baumanii in a tertiary care hospital in India: clinical characteristics, antibiotic susceptibility and molecular characterization.Molecular biology reports · 2024
   Article
2. Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.Biochemical pharmacology · 2021
   Article
3. A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.Antimicrobial agents and chemotherapy · 2020
   Article
4. Colistin-ResistantMicroorganisms · 2020
   Article
5. [New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].Der Anaesthesist · 2019
   Article
6. Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates.mBio · 2019
   Article
7. Unlocking NuriPep 1653 From Common Pea Protein: A Potent Antimicrobial Peptide to Tackle a Pan-Drug ResistantFrontiers in microbiology · 2019
   Article
8. Saudi journal of biological sciences · 2018
   Review
9. Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.Scientific reports · 2017
   Article
10. Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?GMS hygiene and infection control · 2017
    Article
11. Frontiers in microbiology · 2017
    Review
12. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.Clinical microbiology reviews · 2017
    Review
13. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.BMC infectious diseases · 2015
    Article
14. Mechanisms of antimicrobial resistance in Gram-negative bacilli.Annals of intensive care · 2015
    Article
15. Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter baumannii Infections: Evolution of Old Problems and New Challenges for Institutes.International journal of environmental research and public health · 2015
    Review

Corrections and comments

• Comment on
  Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.2015

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as